Evidence map›Paper›PMID 40708824›Full record

ArticlePeerJ2025

P21 activated kinase 6: a promising tool for predicting small cell lung cancer diagnosis and treatment response.

Simei Chen, Kexin Han, Yinyi Chen, Liping Wei, Xinlu Sun, Yi Luo, Lili Wen, Liming Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simei ChenDepartment of Blood Transfusion, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Kexin HanSchool of Public Health, Nanchang University, Nanchang, Jiangxi, China.
Yinyi ChenDepartment of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Liping WeiDepartment of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Xinlu SunSchool of Public Health, Nanchang University, Nanchang, Jiangxi, China.
Yi LuoDepartment of Blood Transfusion, The Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.
Lili WenDepartment of Clinical Laboratory, The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China.
Liming TanDepartment of Clinical Laboratory, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Building upon the established role of P21 Activated Kinase 6 (PAK6) in tumor progression and chemoresistance pathways, we postulate its potential as a dual-function biomarker for small cell lung cancer (SCLC). This investigation aims to conduct a comprehensive evaluation of PAK6's diagnostic validity and prognostic significance through comparative analysis of PAK6 serological levels across distinct clinical cohorts to determine diagnostic thresholds, and its clinical correlation with therapeutic responsiveness. Patients and Methods: This study included 109 patients diagnosed with SCLC, 92 patients with non-small cell lung cancer (NSCLC), 85 patients with pulmonary nodules (PN), and 94 healthy individuals undergoing routine physical examinations as the normal control group (NC). Serum PAK6 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). Additionally, levels of neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and pro-gastrin-releasing peptide (ProGRP) were quantified Results: Serum PAK6 levels were significantly higher in the SCLC group compared to the other three groups ( Conclusion: Serum PAK6 holds significant clinical value for the diagnosis, treatment monitoring, and prognosis evaluation of SCLC and may serve as a potential therapeutic target for the disease.

Indexed as

Biomarkers, TumorLung Neoplasmsp21-Activated KinasesSmall Cell Lung CarcinomaAdultAgedCA-19-9 AntigenCarcinoembryonic AntigenCarcinoma, Non-Small-Cell LungCase-Control StudiesFemaleHumansMaleMiddle AgedPeptide FragmentsPhosphopyruvate HydrataseBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic Antigenp21-Activated KinasesPeptide FragmentsPhosphopyruvate HydrataseNSEPAK6ProGRPSerum tumor markersSmall cell lung cancer

Identifiers

PMID40708824
PMCPMC12288745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.